Clinical trials: T2DM
Type 2 Diabetes Mellitus (T2DM), Cardiovascular Diseases
Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release Tablets
An open label, randomized, two-period, two treatment, two-sequence, crossover, balanced, single dose oral bioequivalence study to compare Empagliflozin/ Linagliptin/ Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet versus…
- Trial name
- NCT07872358
- Testing
- Empagliflozin/Linagliptin/Metformin HCl Extended Release Tablet, Trijardy® XR Tablets
- Where
- India
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Cardiovascular Diseases, Type 2 Diabetes Mellitus (T2DM)
EValuation Of poLygenic Scores and CT imAging In Risk Factor Modification in Patients With diabEtes
This study is a three-arm, parallel-group, randomised controlled trial evaluating the effect of using cardiac CT imaging or polygenic risk score in cardiovascular risk factor modification in patients with diabetes.
- Trial name
- VOLTAIRE (NCT07091162)
- Testing
- CTCA results, PRS results
- Where
- Australia
- Volunteers
- 79 people
- Sponsor
- Monash University
Obesity, Overweight
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA) being developed for chronic weight…
- Conditions
- Obesity, Overweight, Type 2 Diabetes Mellitus (T2DM)
- Trial name
- NCT07670416
- Testing
- Enicepatide
- Where
- 21 sites in China
- Volunteers
- 300 people
- Sponsor
- Hoffmann-La Roche
Alzheimer Disease, Dementia
Preventing Medication Mismanagement in People Living With Dementia Through Automated Medication Dispensing With Facial Recognition and Video Observation
Globally, >47M individuals live with dementia, with new incidence of 7.7M annually. Medication mismanagement is one of the most common and concerning risk factors in people with dementia (PwD), as it leads to undertreatment…
- Conditions
- Alzheimer Disease, Dementia, Medication Adherence, Type 2 Diabetes Mellitus (T2DM)
- Trial name
- NCT06691256
- Testing
- HiDO-ALZ
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- HiDO Technologies
Periodontitis, Type 2 Diabetes Mellitus (T2DM)
Para-Probiotic Oral Care in Periodontal Patients With Type 2 Diabetes
This randomized controlled clinical trial aims to evaluate the effectiveness of a para-probiotic-based oral care protocol in improving periodontal health and glycemic control in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- PPDM2 (NCT07069166)
- Testing
- Para-probiotic oral care, Chlorhexidine oral care
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- University of Pavia
Insulin Dependent Diabetes, Diabetes (DM)
Integrating New Skills Into Diabetes Education With CGM
This study is designed to test the preliminary efficacy of a three-stage continuous glucose monitor (CGM) integration program for older adults who are taking insulin.
- Conditions
- Insulin Dependent Diabetes, Diabetes (DM), Diabetes (Insulin-requiring, Type 1 or Type 2), Diabetes Education
- Trial name
- INSIDE-CGM (NCT07463209)
- Testing
- Three-stage CGM integration program, One-time clinic-based CGM training, Self-directed CGM training
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- University of North Carolina, Chapel Hill
Chronic Kidney Disease(CKD), Type 2 DM
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)
IRIS-CKD is an implementation study to improve guideline-recommended screening of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.
- Conditions
- Chronic Kidney Disease(CKD), Type 2 DM, Type 2 Diabetes Mellitus (T2DM)
- Trial name
- IRIS-CKD (NCT06906627)
- Testing
- (IRIS-CKD Screening Program): Home Kit, (IRIS-CKD Screening Program): Standard Lab Order
- Where
- 7 sites in United States
- Volunteers
- 500 people
- Sponsor
- Duke University
Chronic Kidney Disease(CKD), Type 2 DM
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)
IRIS-CKD is a two-program implementation study to improve guideline-recommended screening and treatment of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.
- Conditions
- Chronic Kidney Disease(CKD), Type 2 DM, Type 2 Diabetes Mellitus (T2DM)
- Trial name
- IRIS-CKD (NCT06906640)
- Testing
- (IRIS-CKD Management Program): Education, (IRIS-CKD Management Program): GDMT
- Where
- 7 sites in United States
- Volunteers
- 212 people
- Sponsor
- Duke University
Type 2 Diabetes (T2DM)
Pancreatin Added to Standard Antihyperglycemic Therapy in Patients With Type 2 Diabetes
Medications that enhance the incretin effect (GLP-1 receptor agonists, tirzepatide (GIP/GLP-1 receptor agonist) and DPP-4 inhibitors) are used in treatment of patients with type 2 diabetes.
- Trial name
- NCT07852988
- Testing
- Pancreatin
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Silesian Centre for Heart Diseases
Type 2 Diabetes (T2DM), Obesity Type 2 Diabetes Mellitus
DIabetes GLycemic Assessment in Newly Confirmed Episodes
This is a prospective, open-label, randomized controlled trial involving 80 adult patients with newly diagnosed T2DM (diagnosed within the last 3 months) recruited at the Bogomolets National Medical University.
- Conditions
- Type 2 Diabetes (T2DM), Obesity Type 2 Diabetes Mellitus, Obesity & Overweight, Insulin Resistance
- Trial name
- DI-GLANCE (NCT07690163)
- Testing
- CGM Sibionics, On-Call Extra Glucometer
- Where
- 3 sites in Ukraine
- Volunteers
- 80 people
- Sponsor
- Nazarii Kobyliak
Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes
Using Continuous Glucose Monitoring to Quantify the Effects of NOURISH's Culturally Modified Meals on Asian Americans With Type 2 Diabetes
The investigators are hoping to determine whether tailoring the diet of someone with type 2 diabetes to their ethnic group while following American Diabetes Association guidelines can make a significant difference in their blood…
- Trial name
- NCT06836479
- Testing
- NOURISH Diet, Self-Selected Diet (Control)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Type 2 Diabetes, Type 2 Diabetes (T2DM)
PLEASURE (Pleasing Lovers, Efficacy, Arousal, Satisfaction, and Uptake Research on Eroxon)
The purpose of this research study is to look at whether Eroxon® gel when used together with tadalafil, may help improve erectile function in men ages 18 to 40 who have type 2 diabetes.
- Trial name
- NCT07636161
- Testing
- Eroxon®, tadalafil
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Miami
Type 2 Diabetes Mellitus (T2DM), Atherosclerosis
Colchicine for Primary Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes
This study will test whether a low-cost anti-inflammatory medicine called colchicine can help protect the blood vessels of people with type 2 diabetes.
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Atherosclerosis, Cardiovascular Diseases
- Trial name
- Col-DM (NCT07837934)
- Testing
- Colchicine 0.5 MG Oral Tablet Once Daily
- Where
- Singapore
- Volunteers
- 300 people
- Sponsor
- Tan Tock Seng Hospital
T2DM (Type 2 Diabetes Mellitus)
Pilot Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets
This is a pilot bioequivalence study. It is a randomized, open-label, single-dose, crossover study. The primary objective of this study is to preliminarily evaluate the pharmacokinetic parameters and their variability of the test…
- Trial name
- NCT07412015
- Testing
- treatment T (dose 1), treatment T (dose 2), treatment R (dose 1)
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chipscreen Biosciences, Ltd.
T2DM (Type 2 Diabetes Mellitus)
Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets
This is a single-center, randomized, open-label, two-period, two-sequence crossover bioequivalence study under fed conditions. The primary objective is to evaluate the bioequivalence of a single oral dose of the test formulation…
- Trial name
- NCT07519265
- Testing
- Chiglitazar/Metformin extended-release fixed-dose combination tablet, dose 1, Chiglitazar tablet, dose 1, Metformin extended-release tablet, dose 1
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Chipscreen Biosciences, Ltd.
Type 2 Diabetes Mellitus (T2DM), Recurrent Urinary Tract Infections
Cranberry Proanthocyanidins and Lactobacilli for Recurrent UTI Prevention in Type 2 Diabetes
The purpose of this prospective, single-arm feasibility study was to evaluate the operational feasibility, tolerability, safety, and exploratory clinical outcomes of an oral supplement combining standardized cranberry…
- Trial name
- NCT07832409
- Testing
- Cranberry Proanthocyanidins and Lactobacilli
- Where
- Georgia
- Volunteers
- 100 people
- Sponsor
- National Institute of Endocrinology, Georgia
Type 2 Diabetes (T2DM), Diabetic Nephropathies
A Multicenter Randomized Double-Blind Trial of Chrocare CDSS for Integrated Management of Type 2 Diabetes
This is a multicenter, randomized, double-blind, parallel-group clinical study for adults with type 2 diabetes and early diabetic kidney or retinal complications.
- Conditions
- Type 2 Diabetes (T2DM), Diabetic Nephropathies, Diabetic Retinopathy (DR)
- Trial name
- Chrocare-DM (NCT07833228)
- Testing
- AI large language model-based clinical decision support system, Standard diabetes integrated management formulated by endocrinologists
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Type 2 Diabetes Mellitus (T2DM)
UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study
The purpose of this study is to evaluate the efficacy of UBT251 injection after 24 weeks of continuous administration in patients with type 2 diabetes mellitus and to recommend the dosing regimen for the Phase III clinical trial.
- Trial name
- T2DM (NCT07163624)
- Testing
- Semaglutide Injection (Ozempic®)
- Where
- China
- Volunteers
- 211 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
T2DM (Type 2 Diabetes Mellitus)
A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus
This randomized, double-blind, placebo-controlled Phase II study is designed to evaluate the efficacy, safety, and tolerability of ASC30 oral tablets formulation in participants with Type 2 Diabetes Mellitus
- Trial name
- NCT07321678
- Testing
- ASC30 tablets
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Ascletis Pharma (China) Co., Limited
Type 2 Diabetes Mellitus (T2DM), Mild Cognitive Impairment (MCI)
The Cognitive Protective Effect of VR-based Cognitive Training in Type 2 Diabetes Patients With Mild Cognitive Impairment
A multi-center prospective, open-label, parallel-group randomized controlled trial is conducted to investigate the cognitive-protective efficacy of a novel, diabetes-specific virtual reality (VR)-based cognitive training system…
- Trial name
- NCT07650318
- Testing
- VR-Based Cognitive Training Plus Standard Diabetes Care, Traditional Paper-and-Pencil Cognitive Training Plus Standard Diabetes Care
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School